Patent to diagnose MS based on Kir4.1

A forum to discuss Chronic Cerebrospinal Venous Insufficiency and its relationship to Multiple Sclerosis.

Patent to diagnose MS based on Kir4.1

Postby frodo » Wed Jun 25, 2014 11:09 am

Maybe this is not very related to CCSVI, or maybe it is. In any case is worth to share it.

Means and methods for diagnosing and treating multiple sclerosis
US 20140080156 A1

http://www.google.com/patents/US20140080156

ABSTRACT

This invention relates to a peptide comprising or consisting of at least 8 consecutive amino acid residues of the sequence set forth in SEQ ID NO: 3, provided that said peptide does not consist of the sequence set forth in SEQ ID NO: 3, or a corresponding peptidomimetic, wherein said peptide or peptidomimetic binds to an anti-KIR4.1 antibody comprised in a sample from a patient, said patient having multiple sclerosis or a predisposition therefor, wherein preferably (i) said at least 8 consecutive amino acid residues are a subsequence of an extracellular domain of KIR4.1, said extracellular domain consisting of the sequence set forth in SEQ ID NO: 1 or 2; or (ii) said peptide comprises or consists of the sequence of SEQ ID NO: 1 or 2. The present invention furthermore relates to a method for diagnosing multiple sclerosis or a predisposition for multiple sclerosis in a subject, the method comprising determining the presence of an anti-KIR4.1 antibody in a sample obtained from said subject, wherein the presence of an anti-KIR4.1 antibody in said sample is indicative of multiple sclerosis or a predisposition for multiple sclerosis. Also provided are novel means and methods for the therapy of multiple sclerosis.
User avatar
frodo
Family Elder
 
Posts: 619
Joined: Wed Dec 02, 2009 3:00 pm

Advertisement

Re: Patent to diagnose MS based on Kir4.1

Postby cheerleader » Wed Jun 25, 2014 4:15 pm

I wrote up a blog post on KIR4.1 and the big picture. Researchers have found KIR4.1 (a potassium channel protein important in myelination) antibodies are higher in plasma for pre-clinical MS patients, when compared to healthy controls. But it's not all people with MS, only about half. But why? Where else do we see this happen?
There is a connection to cerebral edema and hydrocephalus--- and yes, this could be related to slowed venous drainage due to CCSVI.
more here:
http://ccsviinms.blogspot.com/2014/02/k ... cture.html

cheer
Husband dx RRMS 3/07
dx dual jugular vein stenosis (CCSVI) 4/09
http://ccsviinms.blogspot.com
User avatar
cheerleader
Family Elder
 
Posts: 5073
Joined: Mon Sep 10, 2007 2:00 pm
Location: southern California

Re: Patent to diagnose MS based on Kir4.1

Postby frodo » Sun Nov 16, 2014 4:11 pm

After some months without hearing from kir4.1 it is back, but now it seems that it is not considered pathogenic anymore, but a biomarker instead.

http://www.ncbi.nlm.nih.gov/pubmed/25392324

Increased anti-KIR4.1 antibodies in multiple sclerosis: Could it be a marker of disease relapse?
Brill L1, Goldberg L1, Karni A2, Petrou P1, Abramsky O1, Ovadia H1, Ben-Hur T1, Karussis D1, Vaknin-Dembinsky A3.
Author information
Abstract
BACKGROUND:
Screening of putative autoimmune targets in multiple sclerosis (MS) revealed a proportion of patients carrying antibodies (Abs) against KIR4.1, a potassium channel that shares functional properties with AQP4. Both are localized at the perivascular astrocytic processes.

AIMS:
To measure anti-KIR4.1 Abs in the serum of MS and neuromyelitis optica (NMO) patients, and to identify the clinical and laboratory characteristics of patients harboring anti-KIR4.1 Abs.

METHODS:
We measured anti-KIR4.1 Abs in serum, using the peptide KIR4.1 (83-120) enzyme-linked immunosorbent assay (ELISA).

RESULTS:
Serum levels of anti-KIR4.1 Abs were significantly higher in MS and NMO patients than in healthy controls (HCs); with Abs detected in 21 of 80, 10 of 45, and 2 of 32 individuals, respectively (MS versus HC, p < 0.05). The level of anti-KIR4.1 Abs was significantly higher during MS relapse, versus remission (p = 0.04). The clinical characteristics of our study patients did not vary based on KIR4.1 positivity.

CONCLUSIONS:
Anti-KIR4.1 Abs were found in similar proportions of patients with MS and NMO, at a significantly higher level than observed in HCs; consequently, the presence of Abs does not discriminate between these demyelinating diseases. However, anti-KIR4.1 Ab levels differed in MS patients during relapse and remission; as such, they may represent a marker of disease exacerbation.

© The Author(s), 2014.

KEYWORDS:
User avatar
frodo
Family Elder
 
Posts: 619
Joined: Wed Dec 02, 2009 3:00 pm


Return to Chronic Cerebrospinal Venous Insufficiency (CCSVI)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service